<DOC>
	<DOCNO>NCT01435993</DOCNO>
	<brief_summary>This study investigate experimental new drug , GSK1223249 patient diagnose relapse form multiple sclerosis . The study specifically investigate safety ( vital sign like heart rate , blood pressure , Magnetic Resonance Imaging ( MRI ) , marker health blood sample ) , tolerability ( side effect occur , ) , pharmacokinetics ( body process drug long drug stay blood , cerebro-spinal fluid ) . The study also investigate patient ' immune system interact GSK1223249 .</brief_summary>
	<brief_title>Multiple Doses Anti-NOGO A Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description>This study randomise , placebo-controlled , single-blind ( Investigator Subject ) , single repeat ascend dose protocol , multiple sclerosis patient . The study design evaluate safety , tolerability , pharmacokinetics , potential immunogenicity GSK1223249 ( monoclonal antibody raise Nogo-A ) , give intravenously Multiple Sclerosis patient . The study also evaluate exploratory endpoint include para-clinical activity via magnetic resonance imaging , cerebrospinal fluid pharmacokinetics , effect repeat dose administration GSK1223249 disability . Furthermore MS symptom , relapse individual symptom severity closely monitor .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Diagnosed relapse form MS . Using one follow ongoing MS treatment strategy , define 1 . Currently receive Betainterferon/Copaxone treatment MS receive current course therapy 3 month prior screen , OR 2 . Not currently receive disease modify therapy treatment MS , receive therapy least 3 month prior screen . Demonstrated clinical activity 2 year prior screen , whilst receive current/previous treatment regimen prior treatment regimen Expanded Disability Status Scale ( EDSS ) score â‰¤6.0 either screen baseline visit . Male female 18 60 year age inclusive , time signing informed consent . Body weight equal great : 50 kilogrammes Complications/History disease may impact safety patient enrol study . Liver function test outside normal range patient population Treatment methylprednisolone systemic steroid , relapse otherwise , within 30 day screen Treatment past 6 month follow agent : Fingolimod ( Gilenya ) , methotrexate , mitoxantrone , azathioprine , small molecule immunosuppressant . History anaphilaxis protein base therapeutic monoclonal antibody . Positive result Hapatitis B , HIV , and/or drug abuse , excessive alcohol consumption . Not able undergo MRI scan safely , Gadolinium ( contrast enhance agent ) MRI . Other significant infection e.g . Tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis , Secondary-Progressive relapse</keyword>
</DOC>